• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Type 2 Diabetes Mellitus Treatment Market Analysis

    ID: MRFR/Pharma/4214-HCR
    85 Pages
    Rahul Gotadki
    October 2025

    Type 2 Diabetes Mellitus Treatment Market Research Report Information By Treatment (Drug (Insulin, Sensitizers, Sglt-2, Alpha-Glucosidase Inhibitors, Others), Devices (Blood Glucose Monitoring, Insulin Delivery Devices)), By The End User – Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Type 2 Diabetes Mellitus Treatment Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Analysis

    Type 2 Diabetes Mellitus Treatment Market (Global, 2024)

    Introduction

    Type 2 diabetes treatment market is set to witness a number of transformations as the global health care system prepares to cope with the rising prevalence of this chronic condition. The burgeoning focus on precision medicine and innovation is leading to a proliferation of new treatment options, including new pharmacological agents, digital health solutions, and lifestyle intervention programs. Awareness of the importance of early diagnosis and treatment is generating demand for effective treatment options. Moreover, the increasing use of technology, such as continuous glucose monitoring and telehealth, is transforming patient engagement and adherence to treatment. As pharmaceutical companies, physicians, and policymakers attempt to cope with the evolving landscape, an understanding of the dynamics of the type 2 diabetes treatment market will be critical to improving patient outcomes and addressing the global diabetes epidemic.

    PESTLE Analysis

    Political
    In 2024, the government's policy against diabetes led to the increase of research and treatment. The United States government gave $ 1.5 billion to the National Institutes of Health for diabetes research. This showed a strong commitment to the increasing occurrence of Type 2 diabetes. Various countries also tightened up regulations on sugar in food. The British government introduced a sugar tax that has raised more than £400 million since it came into effect. The money has been reinvested in public health.
    Economic
    In the U.S., the total spending on health care is expected to reach $ 4 Trillion by 2024. This increase is partly due to the rising costs of diabetes care, which includes medications, hospitalization and outpatient care. The average annual cost of diabetes per patient is $16,750, with about $ 9,600 going toward direct medical costs. This imposes a heavy burden on both the individual and the health care system.
    Social
    Type II diabetes has been a major concern of the public for some time. As of 2024, 342 million adults in the United States were diabetic. The government has focused on a public health campaign, stressing the importance of a healthy lifestyle. There has been a significant increase in participation in diabetes prevention programs. The increase in enrollment was about 25 percent. Also, the stigma of diabetes is gradually being reduced as more people speak out about their experiences and advocate for better management and treatment.
    Technological
    In the field of diabetes, technological progress is rapidly developing, and the world market for diabetes devices is expected to reach $26 billion by 2024. Glucose monitors and devices for injecting insulin are becoming more and more accessible. There are already more than three million users of continuous monitors in the United States. And telehealth services have increased in diabetes care, with a reported increase of 60 percent in the number of virtual consultations for patients with diabetes.
    Legal
    The legal framework regulating the treatment of diabetes is becoming stricter. In 2024 the Food and Drug Administration (FDA) approved twelve new diabetes drugs, thereby showing a premeditated concern for the safety and effectiveness of these drugs. The Affordable Care Act, which requires that diabetes screening and preventive services be covered by health insurance plans without co-payments, has benefited millions of people. It is important for pharmaceutical companies and health care institutions to abide by these regulations to avoid fines.
    Environmental
    Environmental factors are becoming increasingly important in the treatment of type 2 diabetes mellitus, particularly in relation to the sustainable management of medical waste. In 2024, it is estimated that the health care sector will generate about 5.9 million tons of medical waste, of which a significant proportion will consist of diabetes-related items such as syringes and test strips. Efforts are being made to reduce this waste, and initiatives are being launched to encourage the reuse and proper disposal of medical waste and the development of biodegradable medical products.

    Porter's Five Forces

    Threat of New Entrants
    The barriers to entry in the treatment of type 2 diabetes are moderate, as the market requires significant investment in research and development, regulatory approvals, and the establishment of distribution channels. However, the growing demand for innovation and the high potential returns may attract new players to the market, resulting in a moderate threat level.
    Bargaining Power of Suppliers
    The power of suppliers on the market is relatively weak, as there are many suppliers of raw materials and pharmaceuticals. There are many suppliers, and the companies can easily change the supplier, which reduces the power of the supplier.
    Bargaining Power of Buyers
    The buyers in the Type 2 diabetes treatment market, that is, the hospitals and the patients, have high bargaining power. The treatment options are many and the demand for cost-effectiveness is high. The increasing availability of generics and the increasing demand for individualized treatment make the buyers’ power even greater.
    Threat of Substitutes
    The threat of substitutes is moderate. Several treatment options are available, such as lifestyle changes, dietary changes and non-pharmaceutical treatments. However, the effectiveness and acceptance of these alternatives may vary, which may limit their impact on the market.
    Competitive Rivalry
    Competition is High - The competition in the Type 2 diabetes mellitus treatment market is high because of the presence of a large number of established pharmaceutical companies and the constant introduction of new therapies. The companies compete with each other through aggressive marketing, product differentiation, and innovation in order to gain market share.

    SWOT Analysis

    Strengths

    • Increasing prevalence of Type 2 diabetes driving demand for treatment options.
    • Advancements in technology leading to innovative treatment solutions.
    • Strong pipeline of new drugs and therapies under development.

    Weaknesses

    • High cost of new treatments may limit accessibility for some patients.
    • Complexity of treatment regimens can lead to poor patient adherence.
    • Limited awareness and education about Type 2 diabetes management.

    Opportunities

    • Growing focus on preventive healthcare and lifestyle management.
    • Expansion of telemedicine and digital health solutions for diabetes care.
    • Potential for partnerships with tech companies to enhance treatment delivery.

    Threats

    • Regulatory challenges and lengthy approval processes for new therapies.
    • Intense competition among pharmaceutical companies in the diabetes market.
    • Economic downturns affecting healthcare budgets and patient spending.

    Summary

    The type-2 diabetes treatment market in 2024 is characterized by a strong demand, owing to the rising prevalence of the disease and the technological advancements in the treatment. Nevertheless, there are still some obstacles to overcome, such as high costs and the lack of patient compliance. Opportunities exist in the field of preventive care and digital solutions, while regulatory barriers and competition may impact the market dynamics. Strategically, education and partnership building may strengthen market positions.

    Market Summary

    As per Market Research Future Analysis, the Type 2 Diabetes Mellitus Treatment Market was valued at USD 18.53 Billion in 2023 and is projected to grow to USD 39.18 Billion by 2032, with a CAGR of 9.45% from 2024 to 2032. The market is driven by rising technological advancements, increasing prevalence of diabetes, and growing awareness about the condition. Key players are developing novel drugs and devices, such as Ozempic and Steglatro, to address the unmet medical needs. However, challenges such as high treatment costs and side effects may hinder growth. The Americas dominate the market due to high healthcare expenditure and patient population, while Asia Pacific is the fastest-growing region.

    Key Market Trends & Highlights

    The Type 2 Diabetes Mellitus Treatment Market is witnessing significant growth driven by various factors.

    • Market Size in 2023: USD 18.53 Billion
    • Projected Market Size by 2032: USD 39.18 Billion
    • CAGR from 2024 to 2032: 9.45%
    • 9.4% of the U.S. population had diabetes in 2015, equating to 30.3 million people

    Market Size & Forecast

    2023 Market Size USD 18.53 Billion
    2024 Market Size USD 18.86 Billion
    2032 Market Size USD 39.18 Billion
    CAGR (2024-2032) 9.45%

    Major Players

    Abbott Laboratories, Acon Laboratories, Inc., Adocia, Akros Pharma, Amgen, AstraZeneca, Bayer AG, Becton Dickinson and Company, Biocon, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Novartis & Co., Novo Nordisk, Peptron, Pfizer, Roche Diagnostics Ltd., Sanofi, Sunpharma, Takeda Pharmaceuticals

    Market Trends

    The increasing prevalence of Type 2 Diabetes Mellitus is driving a paradigm shift towards more personalized treatment approaches, emphasizing the need for innovative therapies and comprehensive management strategies.

    Centers for Disease Control and Prevention (CDC)

    Type 2 Diabetes Mellitus Treatment Market Market Drivers

    Rising Prevalence of Type 2 Diabetes

    The increasing prevalence of Type 2 Diabetes Mellitus globally is a primary driver for the Global Type 2 Diabetes Mellitus Treatment Market Industry. As lifestyle changes and dietary habits contribute to higher obesity rates, the World Health Organization indicates that the number of adults with diabetes has risen significantly. In 2024, the market is projected to reach 18.9 USD Billion, reflecting the urgent need for effective treatment options. This trend is expected to continue, with estimates suggesting that by 2035, the market could expand to 51.4 USD Billion, highlighting the growing demand for innovative therapies and management solutions.

    Market Segment Insights

    Regional Insights

    Key Companies in the Type 2 Diabetes Mellitus Treatment Market market include

    Industry Developments

    • Q2 2025: ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide At the 85th Scientific Sessions of the American Diabetes Association in June 2025, Eli Lilly's tirzepatide (Mounjaro, Zepbound) was highlighted for its unique mechanism and clinical data supporting its use in type 2 diabetes management. The session provided updated insights into tirzepatide’s FDA-approved indications and its role in personalized treatment plans.

    Type 2 Diabetes Mellitus Treatment Market Regional Analysis

    The Americas dominate the type 2 diabetes mellitus treatment market owing to the presence of patient population, a well-developed technology, high healthcare expenditure, and the presence of the leading players. Due to the rising prevalence of diabetes, various companies, and government associations are actively participating in improving diabetes care. For instance, The Merck Foundation has provided funding of around USD 10,000,000 for the projects designed to improve diabetes care in the United States.

    Europe holds the second position in the type 2 diabetes mellitus treatment market. It is expected that the government support towards research & development expenditure and amendments in reimbursement policies in the healthcare is likely to drive the European market. As per the German maternity guidelines, every pregnant woman can undergo glucose challenge test for the early diagnosis of Gestational diabetes mellitus, and the charges for the test are completely covered by women’s health insurance.

    Asia Pacific is the fastest growing type 2 diabetes mellitus treatment market owing to a huge patient pool, increasing demand, and development in healthcare technology.

    The Middle East & Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities.

    Type 2 Diabetes Mellitus Treatment Market Key Players

    Some of key the players in the global type 2 diabetes mellitus treatment market are: 

    • Abbott Laboratories
    • Acon Laboratories, Inc.
    • Adocia
    • Akros Pharma
    • Amgen
    • AstraZeneca
    • Bayer AG
    • Becton 
    • Dickinson and Company
    • Biocon
    • Boehringer Ingelheim
    • Daiichi Sankyo
    • Eli Lilly
    • Merck
    • Novartis & Co.
    • Novo Nordisk
    • Peptron
    • Pfizer
    • Roche Diagnostics Ltd.
    • Sanofi
    • Sunpharma
    • Takeda Pharmaceuticals

    Intended Audience

    • Pharmaceutical Companies
    • Medical Device Companies
    • Research and Development (R&D) Companies
    • Diagnostic Laboratories
    • Government Research Institute
    • Academic Institutes and Universities

    Future Outlook

    Type 2 Diabetes Mellitus Treatment Market Future Outlook

    The Type 2 Diabetes Mellitus Treatment Market is projected to grow at a 9.54% CAGR from 2024 to 2032, driven by increasing prevalence, technological advancements, and rising healthcare expenditure.

    New opportunities lie in:

    • Develop personalized medicine approaches to enhance treatment efficacy and patient adherence.
    • Invest in digital health solutions for remote monitoring and management of diabetes.
    • Expand access to affordable treatment options in emerging markets to capture new patient demographics.

    By 2035, the market is expected to exhibit robust growth, reflecting advancements in treatment and increased global awareness.

    Market Segmentation

    Type 2 Diabetes Mellitus Treatment Market Segmentation

    Intended Audience
    • Pharmaceutical Companies
    • Medical Device Companies
    • Research and Development (R&D) Companies
    • Diagnostic Laboratories
    • Government Research Institute
    • Academic Institutes and Universities

    Report Scope

    Report Attribute/Metric Details  
      Market Size   USD 39.18 Billion by 2032  
      CAGR   9.45%  
      Base Year 2023  
      Forecast Period   2024-2032  
      Historical Data Market Size 2023 18.53 (USD Billion)
      Forecast Units Market Size 2024 18.86 (USD Billion)
      Report Coverage Market Size 2032 39.18 (USD Billion)
      Segments Covered Compound Annual Growth Rate (CAGR) 9.45 % (2024 - 2032)
      Geographies Covered Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Key Vendors Base Year 2023
      Key Market Opportunities Market Forecast Period 2024 - 2032
      Key Market Drivers Historical Data 2018-2022

     

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    1. diabetes mellitus treatment Market, by treatment
    2. diabetes mellitus treatment Market, by End User
    3. diabetes mellitus treatment Market, by Region
    4. diabetes mellitus treatment industry Chapter 12    Appendix LIST OF TABLES
    5. diabetes mellitus treatment Industry Synopsis,
    6. diabetes mellitus treatment Market Estimates and Forecast,
    7. diabetes mellitus treatment Market by Region,
    8. diabetes mellitus treatment Market by Treatment,
    9. diabetes mellitus treatment Market by End Users,
    10.     North America Type
    11. diabetes mellitus treatment Market by Treatment,
    12.     North America Type
    13. diabetes mellitus treatment Market by End Users,
    14.     US Type
    15. diabetes mellitus treatment Market by Treatment,
    16.     US Type
    17. diabetes mellitus treatment Market by End Users,
    18. diabetes mellitus treatment Market by Treatment,
    19. diabetes mellitus treatment market by End Users,
    20. diabetes mellitus treatment Market by Treatment,
    21. diabetes mellitus treatment Market by End Users,
    22. diabetes mellitus treatment Market by Treatment,
    23. diabetes mellitus treatment Market by End Users,
    24. diabetes mellitus treatment Market by Treatment,
    25. diabetes mellitus treatment Market by End Users,
    26. diabetes mellitus treatment Market by Treatment,
    27. diabetes mellitus treatment Market by End Users,
    28. diabetes mellitus treatment Market by Treatment,
    29. diabetes mellitus treatment market by End Users,
    30. diabetes mellitus treatment Market by Treatment,
    31. diabetes mellitus treatment market by End Users,
    32. diabetes mellitus treatment Market
    33. diabetes mellitus treatment Market
    34. diabetes mellitus treatment market Share, by Treatment
    35. diabetes mellitus treatment market Share, by End Users,
    36. diabetes mellitus treatment market Share, by Region,
    37. diabetes mellitus treatment market Share, by Country,
    38. diabetes mellitus treatment market Share, by Country,
    39. diabetes mellitus treatment market Share, by Country,
    40. diabetes mellitus treatment market Share, by Country,
    41. diabetes mellitus treatment market: Company Share Analysis,

    Type 2 Diabetes Mellitus Treatment Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials